Shop Now Contact

Anti-Human CCR4 (Mogamulizumab Biosimilar)

Cat # Size Price Quantity
5038011 mg$250
5038025 mg$750
50380320 mg$2500

  Bulk/Custom

Product Details

CloneMogamulizumab
ApplicationFlow cytometry, animal model study
Host SpeciesMammalian cells
ReactivityHuman
FormatLiquid
Product DescriptionMogamulizumab Biosimilar, CCR4 Monoclonal Antibody
IsotypeHuman IgG1
Regulatory StatusRUO
ClonalityRecombinant
ImmunogenHuman CCR4
Species specificityHuman
Purity>95% by reducing SDS-PAGE
GradeIn vivo
Storage Conditions4ºC
Maximal Shelf Life12 months
SynonymsCD194
RRIDAB_3739314
Target NameCCR4, CD194, CD-194, CKR4, K5-5, ChemR13, CMKBR4
Antibody TypeRecombinant
Research AreasChemokine receptors, Th2 cells, Tregs, Basophils, Monocytes, NK cells, Asthma, Allergy, Cancer Marker, Chemotaxis
See All FormatsClone Mogamulizumab

Background Information

Mogamulizumab is a humanized monoclonal antibody belonging to the immunoglobulin G1 kappa (IgG1κ) subclass, engineered to specifically recognize and bind to the CC chemokine receptor 4 (CCR4). Structurally, Mogamulizumab is a glycoprotein with a molecular mass of approximately 149 kilodaltons (kDa). It consists of two identical heavy chains and two identical light chains joined by disulfide bonds, forming the typical Y-shaped antibody structure. Produced in mammalian expression systems such as Chinese Hamster Ovary (CHO) cells, it undergoes controlled post-translational modifications to ensure proper folding, stability, and glycosylation patterns essential for its biological function.

The variable regions of Mogamulizumab (the antigen-binding (Fab) fragments) contain complementarity-determining regions (CDRs) responsible for high-affinity recognition of CCR4, which is a seven-transmembrane G protein–coupled receptor expressed on specific subsets of immune cells. These CDRs were derived from murine antibody sequences and grafted onto a human IgG1 framework to preserve target specificity while minimizing nonhuman structural elements. Mogamulizumab is uniquely designed with a defucosylated Fc (fragment crystallizable) region, created through glycoengineering to remove fucose residues from the Fc-linked N-glycan at asparagine 297. This modification significantly enhances the antibody’s binding affinity to Fc gamma receptor IIIa (FcγRIIIa) on effector cells such as natural killer (NK) cells, thereby amplifying antibody-dependent cellular cytotoxicity (ADCC) in in vitro systems.

Functionally, upon binding to CCR4 on target cells, Mogamulizumab can trigger immune effector mechanisms such as ADCC and complement-dependent cytotoxicity (CDC), leading to targeted cell elimination in experimental models. Beyond its cytotoxic potential, CCR4 binding may alter receptor-mediated signaling and downstream chemotactic responses. The Fc–FcRn (neonatal Fc receptor) interaction provides extended serum half-life and molecular stability through recycling.

Data Sheets

Anti-Human CCR4 (Mogamulizumab Biosimilar) TDS

Related Protocols

Flow Cytometry Protocol

Related Products

Anti-Human CD4 Antibody, Clone 004AB

iF488 Anti-Human CD4 Antibody, Clone OKT4-Rec

iF647 Anti-Human CD4 Antibody, Clone OKT4-Rec

PE Anti-Human CD4 Antibody, Clone RPA-T4

Frequently Asked Questions

What are InnoCyto Biosimilar products?
InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.
How similar are these biosimilars to the original therapeutic antibody?
Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.
Are these antibodies suitable for in vivo studies?
Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.
What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?
A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.
What quality and purity standards do biosimilar antibodies meet?
All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.
Which therapeutic targets and mechanisms are covered in the Biosimilar line?
The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.

Have a product or application question? Consult our FAQs or contact us.